Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...

The active ingredient in the popular weight loss drug Wegovy may help treat a type of fatty liver disease, according to a new ...

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

Wegovy (semaglutide) could offer a new option to treat severe liver disease based on new clinical trial evidence. The GLP-1 ...

Semaglutide, a drug commonly taken for weight loss, showed marked benefits for most patients in a trial for metabolic ...

Results showed that 62.9% of patients on Ozempic saw a reduction in liver inflammation, compared to 34.3% on placebo.

A large trial showed that the weight-loss drug could reduce liver inflammation and scarring caused by the common condition.

A late-stage clinical study showed that this weight loss drug helped 2 out of 3 people with the life-threatening liver ...

Prior to starting the trial, the participants also had moderate to high levels of scar tissue in the liver, known as stage 2 ...

Since its historic FDA approval in March 2024 as the first medication for the treatment of the prevalent liver disease ...

The diabetes and weight loss drug semaglutide reversed liver scarring and inflammation. It’s among several drugs in the works for the condition MASH.